These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 1593353)

  • 1. Immune hemolysis, disseminated intravascular coagulation, and serum sickness after large doses of immune globulin given intravenously for Kawasaki disease.
    Comenzo RL; Malachowski ME; Meissner HC; Fulton DR; Berkman EM
    J Pediatr; 1992 Jun; 120(6):926-8. PubMed ID: 1593353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extremely refractory Kawasaki disease with disseminated intravascular coagulation.
    Koh YK; Lee JH; Park YB
    Cardiol Young; 2017 Jul; 27(5):1004-1007. PubMed ID: 28264746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluation of intravenous immune globulin therapy for Kawasaki syndrome.
    Klassen TP; Rowe PC; Gafni A
    J Pediatr; 1993 Apr; 122(4):538-42. PubMed ID: 8463897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Kawasaki disease--two case reports].
    Mroczkowska-Juchniewicz A; Moszyńska B; Pawłowska-Kamieniak A; Szczepanowska A; Papierkowski A
    Pol Merkur Lekarski; 1997 Jul; 3(13):20-1. PubMed ID: 9432293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kawasaki disease presenting with disseminated intravascular coagulation: report of one case.
    Huang LW; Sun W; Huang FY
    Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi; 1994; 35(4):341-4. PubMed ID: 8085458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous gamma-globulin treatment in Kawasaki disease.
    Harada K
    Acta Paediatr Jpn; 1991 Dec; 33(6):805-10. PubMed ID: 1801561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative safety and efficacy of two immune globulin products in Kawasaki disease.
    Rosenfeld EA; Shulman ST; Corydon KE; Mason W; Takahashi M; Kuroda C
    J Pediatr; 1995 Jun; 126(6):1000-3. PubMed ID: 7776074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Possible mechanisms for intravenous immunoglobulin-associated hemolysis: clues obtained from review of clinical case reports.
    Padmore R
    Transfusion; 2015 Jul; 55 Suppl 2():S59-64. PubMed ID: 26174898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
    Tremoulet AH; Jain S; Jaggi P; Jimenez-Fernandez S; Pancheri JM; Sun X; Kanegaye JT; Kovalchin JP; Printz BF; Ramilo O; Burns JC
    Lancet; 2014 May; 383(9930):1731-8. PubMed ID: 24572997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemolytic adverse events with immune globulin products: product factors and patient risks.
    Scott DE; Epstein JS
    Transfusion; 2015 Jul; 55 Suppl 2():S2-5. PubMed ID: 26174893
    [No Abstract]   [Full Text] [Related]  

  • 11. Multiple giant succular and fusiform right and left coronary artery aneurysms after early and adequate treatment of atypical kawasaki disease with unusual presentation.
    Behjati-Ardakani M; Ferdosian F
    Acta Med Iran; 2014; 52(6):490-2. PubMed ID: 25130161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of inflammation in intravenous immune globulin-mediated hemolysis.
    Pendergrast J; Willie-Ramharack K; Sampson L; Laroche V; Branch DR
    Transfusion; 2015 Jul; 55 Suppl 2():S65-73. PubMed ID: 26174900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids.
    Wright DA; Newburger JW; Baker A; Sundel RP
    J Pediatr; 1996 Jan; 128(1):146-9. PubMed ID: 8551407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of a Jehovah's Witness with immune globulin: case of a child with Kawasaki syndrome.
    Roy-Bornstein C; Sagor LD; Roberts KB
    Pediatrics; 1994 Jul; 94(1):112-3. PubMed ID: 8008516
    [No Abstract]   [Full Text] [Related]  

  • 15. Severe Hemolytic Anemia Following Intravenous Immunoglobulin in an Infant With Kawasaki Disease.
    Tocan V; Inaba A; Kurano T; Sonoda M; Soebijanto K; Nakayama H
    J Pediatr Hematol Oncol; 2017 Mar; 39(2):e100-e102. PubMed ID: 27879540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gamma globulin re-treatment in Kawasaki disease.
    Sundel RP; Burns JC; Baker A; Beiser AS; Newburger JW
    J Pediatr; 1993 Oct; 123(4):657-9. PubMed ID: 8410524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IVIG, aspirin, and Kawasaki disease.
    Morgan GJ; MacLeod C; Jenkins J; Stewart C; Craig B
    J Pediatr; 2003 Aug; 143(2):280-1; author reply 281. PubMed ID: 12970651
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of Kawasaki syndrome: a comparison of two dosage regimens of intravenously administered immune globulin.
    Barron KS; Murphy DJ; Silverman ED; Ruttenberg HD; Wright GB; Franklin W; Goldberg SJ; Higashino SM; Cox DG; Lee M
    J Pediatr; 1990 Oct; 117(4):638-44. PubMed ID: 2213395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of intravenous immune globulin on the coagulopathy of Kawasaki syndrome.
    Glode MP; Joffe LS; Wiggins J; Clarke SH; Hathaway WE
    J Pediatr; 1989 Sep; 115(3):469-73. PubMed ID: 2527976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of intravenous immune globulin on the peripheral lymphocyte phenotypes in Kawasaki disease.
    Lee HK; Kim DS; Noh GW; Lee KY
    Yonsei Med J; 1996 Oct; 37(5):357-63. PubMed ID: 8997168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.